The most widely used immunotherapies that have proven clinical efficacy across a wide range of cancers are immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1), PD-L1, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and lymphocyte activation gene-3 (LAG-3). Here, CTLA4 is linked to cancer.